Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access